A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active:	No
Cancer Type:	Gastrointestinal Stromal Tumor (GIST)	NCT ID:	NCT03673501
Trial Phases:	Phase III	Protocol IDs:	DCC-2618-03-002 (primary) NCI-2019-00046
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Deciphera Pharmaceuticals LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT03673501

Summary

This is a 2-arm, randomized, open-label, international, multicenter study comparing the
efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to
first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized
in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or
sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).

Treatment Sites in Georgia

Georgia Cancer Specialists - CenterPointe
1100 Johnson Ferry Road
Suite 600
Sandy Springs, GA 30342
404-256-4777 ext 9242
www.gacancer.com

Doctors:

Rodolfo E. Bordoni MD

Nishan H. Fernando MD

Pradeep C. Jolly MD

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Study Coordinator:

Anila Lokhandwala
404-256-4777 x9242

Doctors:

Rodolfo E. Bordoni MD

Nishan H. Fernando MD

Pradeep C. Jolly MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.